Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among Patients with NSCLC and the Risk of Death From Any Cause Among Patients with Solid Tumours By Ogkologos - May 7, 2025 706 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the analysis of TRACERx and MSK-IMPACT studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Newly Developed RSClin Provides Prognostic Information in HR-positive, HER2-negative Early Breast... January 14, 2021 Multiple Myeloma Awareness Month: Inequity and Disparities in Multiple Myeloma Diagnosis,... March 1, 2021 EMA Recommends Extension of Indications for Niraparib September 29, 2020 A real Eureka moment for translation February 10, 2023 Load more HOT NEWS Can Artificial Intelligence Help See Cancer in New, and Better, Ways? How Finding the Right Primary Care Physician During Cancer Has Helped... EMA Recommends Granting a Marketing Authorisation for Celdoxome Pegylated Liposomal SIOG 2020: New Research in Caring for and Treating People With...
